Stockreport

Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G

MOMENTA PHARMACEUTICALS  (MNTA) 
Last momenta pharmaceuticals earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.momentapharma.com/investor-relations
PDF CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel b [Read more]